WORCESTER, Mass. and TORONTO, May 8, 2012 /PRNewswire/ — Generex Biotechnology Corporation (OTCBB: GNBT) announced today that abstracts featuring the AE37 breast cancer vaccine clinical program of Generex wholly-owned subsidiary Antigen Express, Inc. will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (http://chicago2012.asco.org) taking place June 1-5, 2012 in Chicago, IL.
An abstract entitled “From bench to bedside: The use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines” will be the subject of an oral presentation on Monday, June 4, 2012 at 5:30 pm CDT during the session on Developmental Therapeutics – Clinical Pharmacology and Immunotherapy. This abstract was recognized with a 2012 Conquer Cancer Foundation of ASCO Merit Award bestowed by the Conquer Cancer Foundation of the American Society of Clinical Oncology and the 2012 Scientific Program Committee. The merit award program was established to recognize high quality abstracts.